Linker Information

General Information of This Linker
Linker ID
LIN0QZMPK
Linker Name
Phenoxy silyl linker 39
Linker Type
Reduction sensitive linker
Antibody-Linker Relation
Cleavable
Structure
Formula
C40H57N11O13S2
Isosmiles
C=CS(NC1=CC(NS(C=C)(=O)=O)=CC(C(NCN2C=C(CCOCCOCCOCC(N[C@H](C(N[C@@H](CCCNC(N)=O)C(NC3=CC=C(C=C3)CO)=O)=O)C(C)C)=O)N=N2)=O)=C1)(=O)=O
InChI
InChI=1S/C40H57N11O13S2/c1-5-65(58,59)48-32-20-29(21-33(22-32)49-66(60,61)6-2)37(54)43-26-51-23-31(47-50-51)13-15-62-16-17-63-18-19-64-25-35(53)46-36(27(3)4)39(56)45-34(8-7-14-42-40(41)57)38(55)44-30-11-9-28(24-52)10-12-30/h5-6,9-12,20-23,27,34,36,48-49,52H,1-2,7-8,13-19,24-26H2,3-4H3,(H,43,54)(H,44,55)(H,45,56)(H,46,53)(H3,41,42,57)/t34-,36-/m0/s1
InChIKey
PESLJEFFQGFNIT-GIWKVKTRSA-N
Pharmaceutical Properties
Molecule Weight
964.094
Polar area
342.49
Complexity
2187.580077
xlogp Value
0.2334
Heavy Count
66
Rot Bonds
31
Hbond acc
16
Hbond Donor
9
Each Antibody-drug Conjugate Related to This Linker
Full Information of The Activity Data of The ADC(s) Related to This Linker
39914224 Ate-39 [Investigative]
 ADC Info 
Revealed Based on the Cell Line Data
Click To Hide/Show 4 Activity Data Related to This Level
Experiment 1 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal inhibitory Concentration (lC50)
15.88 nM
Moderate PD-L1 expression (PD-L1++)
Method Description
The starting point of the small molecule drug was 500 nM, and the drug was diluted 5 times sequentially, for a total of eight concentration points. Cells were laid on 96-well plate at 4000 cells/well, cultured overnight and were added with diluted drugs, in the incubator for 72 h. All cells incubated with the drug were tested for cell viability using Cell Counting Kit-8 (CCK-8) kit (Meilunbio, Dalian, China).

   Click to Show/Hide
In Vitro Model Colon carcinoma HCT116 cells CVCL_0291
Experiment 2 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal inhibitory Concentration (lC50)
25.55 nM
Moderate PD-L1 expression (PD-L1++)
Method Description
The starting point of the small molecule drug was 500 nM, and the drug was diluted 5 times sequentially, for a total of eight concentration points. Cells were laid on 96-well plate at 4000 cells/well, cultured overnight and were added with diluted drugs, in the incubator for 72 h. All cells incubated with the drug were tested for cell viability using Cell Counting Kit-8 (CCK-8) kit (Meilunbio, Dalian, China).

   Click to Show/Hide
In Vitro Model Colon carcinoma HCT116 cells CVCL_0291
Experiment 3 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal inhibitory Concentration (lC50)
25.7 nM
Positive PD-L1 expression (PD-L1+++/++)
Method Description
The starting point of the small molecule drug was 500 nM, and the drug was diluted 5 times sequentially, for a total of eight concentration points. Cells were laid on 96-well plate at 4000 cells/well, cultured overnight and were added with diluted drugs, in the incubator for 72 h. All cells incubated with the drug were tested for cell viability using Cell Counting Kit-8 (CCK-8) kit (Meilunbio, Dalian, China).

   Click to Show/Hide
In Vitro Model Glioblastoma U87 cells CVCL_0022
Experiment 4 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal inhibitory Concentration (lC50)
68.49 nM
Moderate PD-L1 expression (PD-L1++)
Method Description
The starting point of the small molecule drug was 500 nM, and the drug was diluted 5 times sequentially, for a total of eight concentration points. Cells were laid on 96-well plate at 4000 cells/well, cultured overnight and were added with diluted drugs, in the incubator for 72 h. All cells incubated with the drug were tested for cell viability using Cell Counting Kit-8 (CCK-8) kit (Meilunbio, Dalian, China).

   Click to Show/Hide
In Vitro Model Colon carcinoma HCT116 cells CVCL_0291
References
Ref 1 Fine-tuning phenoxy silyl scaffolds for the development of glutathione-responsive prodrugs and antibody-drug conjugates